Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Nektar Therapeutics

+ Add to Watchlist


10.801 EUR 0.269 2.43%

As of 15:11:14 ET on 04/17/2015.

Company Profile for Nektar Therapeutics (ITH)

Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. The Company's product pipeline is comprised of early to late stage drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology.

Contact Information

Nektar Therapeutics

455 Mission Bay Blvd South
San Francisco, CA 94158
United States
Phone: 1-415-482-5300
Fax: 1-415-339-5300

Key Executives for Nektar Therapeutics (ITH)

Howard W RobinPresident/CEOJohn L NicholsonSenior VP/CFO
Stephen K DobersteinSenior VP/Chief Scientific OfcrGil M LabrucherieSenior VP/Secy/Gen Counsel
Ivan P GergelSenior VP:Drug Dev/Chief Medical OfcrJillian B ThomsenSenior VP:Finance
Maninder HoraSenior VP:Pharmaceutical DevJennifer RuddockVP:Investor Relations

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

sec ||= nil